BusinessCanada1 sourcesNeutral

Biogen's Litifilimab Shows Promise In Cutaneous Lupus Study

Biogen Inc. (BIIB) announced positive results from Part A of the AMETHYST Phase 2/3 study of litifilimab in people living with cutaneous lupus erythematosus (CLE).

rttnews

via Rttnews

March 30, 2026 | 1:56 AM UTCUpdated 2h ago

Share Read original

Read the full article at Rttnews →

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Rttnews

NewsDataCA

Comments

0 comments

Be respectful and constructive.

Loading comments...

Sysco To Buy Cash & Carry Firm Jetro Restaurant Depot; Backs Outlook, Pauses Buyback; Stock Down

Unknown-5h ago-3 sources

Biogen's Litifilimab Shows Promise In Cutaneous Lupus Study

Source Verification

Comments

UCLA headed back to Final Four after comeback against Duke

Australia to halve excise on fuel to bring down costs, PM Albanese says

Related Articles

Digicel expands retail and connectivity footprint with new store in Ocho Rios

Shanghai Electric Group Co., Ltd. Profit Climbs In Full Year

Sysco To Buy Cash & Carry Firm Jetro Restaurant Depot; Backs Outlook, Pauses Buyback; Stock Down